ASLAN Pharmaceuticals Announces Topline Results From TreeTopp Global Pivotal Study of Varlitinib in Biliary Tract Cancer
November 11, 2019 03:21 ET
|
ASLAN PHARMACEUTICALS LIMITED
- The study did not meet its co-primary endpoints. The primary analysis of PFS yielded a hazard ratio of 0.90 in favour of varlitinib, and the ORR for varlitinib was 9.4% versus 4.8% in the control...
ASLAN Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
October 31, 2019 03:37 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Oct. 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for...
ASLAN Pharmaceuticals Announces Closing of US$3 Million Loan Facility
October 18, 2019 03:35 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Oct. 18, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced it has secured a US$3...
ASLAN Pharmaceuticals Completes Enrolment for Global Pivotal TreeTopp Study Ahead of Schedule
January 02, 2019 03:48 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Jan. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...